Lialda is a prescription medication used to treat ulcerative colitis, a type of inflammatory bowel disease that causes inflammation and sores in the lining of the large intestine. It is FDA-approved for two specific purposes: bringing active flares of mild to moderate ulcerative colitis under control (called induction of remission) and keeping symptoms from returning once they’ve settled down (maintenance of remission). The active ingredient is mesalamine, an anti-inflammatory compound that works directly in the colon rather than throughout the entire body.
How Lialda Works in the Colon
Lialda uses a specialized delivery system to get its active ingredient to the right place. The tablet has a pH-sensitive outer coating that stays intact through the stomach and small intestine, only dissolving once it reaches the end of the small intestine where conditions become less acidic (pH 7 or above). From there, mesalamine gradually releases from the tablet core as it travels through the colon.
This targeted delivery matters because ulcerative colitis affects the colon specifically. By concentrating the medication where the inflammation actually is, Lialda reduces inflammation locally without flooding the rest of the body with the drug. The tablet core contains a mix of water-attracting and fat-attracting ingredients that help mesalamine disperse evenly across the full length of the colon, rather than dumping it all in one spot.
Standard Dosing for Adults
During an active flare, the typical dose is two to four 1.2-gram tablets taken once daily with a meal, for a total daily dose of either 2.4 grams or 4.8 grams. This induction phase generally lasts about eight weeks. Once symptoms are under control, the maintenance dose drops to two 1.2-gram tablets once daily (2.4 grams total), also taken with food.
The once-daily dosing is one of Lialda’s practical advantages. Many other mesalamine formulations require two or three doses spread throughout the day, which can be harder to stick with long term. You need to swallow the tablets whole, not crush, split, or chew them. Breaking the outer coating defeats the delayed-release design and prevents the medication from reaching your colon intact.
Pediatric Use
Lialda is also approved for children with mild to moderate ulcerative colitis, as long as they weigh at least 24 kilograms (about 53 pounds) and can swallow tablets whole. Dosing is based on weight:
- 24 to 35 kg: 2.4 grams daily during the first eight weeks, then 1.2 grams daily for maintenance
- Greater than 35 to 50 kg: 3.6 grams daily for the first eight weeks, then 2.4 grams daily
- Greater than 50 kg: 4.8 grams daily for the first eight weeks, then 2.4 grams daily
Common Side Effects
Lialda is generally well tolerated. In clinical trials lasting eight weeks, the most frequently reported side effects were headache and gas. Among patients taking the lower 2.4-gram daily dose, headache occurred in 5.6% and flatulence in 4%. At the higher 4.8-gram dose, rates were actually slightly lower: 3.4% for headache and 2.8% for flatulence. For context, only 0.6% of patients on placebo reported headaches in those same trials.
A small number of patients showed abnormal liver function tests during treatment, about 2.2% at the higher dose compared to 1.1% on placebo. This is usually detected through routine blood work rather than symptoms you’d notice on your own. Most side effects in trials were mild and didn’t lead people to stop taking the medication.
Kidney Function and Monitoring
One important consideration with Lialda is its potential effect on kidney function. Mesalamine-based medications can, in rare cases, cause kidney problems. Because of this, your doctor will typically check your kidney function before you start treatment and then periodically throughout. This is especially relevant if you already have reduced kidney function or take other medications that stress the kidneys, such as certain pain relievers.
The monitoring itself is straightforward, usually just a blood test. Most people on Lialda never develop kidney issues, but catching any changes early is key to preventing lasting damage. If your kidney function does decline, your doctor may adjust the dose or switch you to a different treatment.
Who Should Not Take Lialda
Lialda contains mesalamine, which is chemically related to aspirin and other salicylates. If you have a known allergy or hypersensitivity to salicylates or to mesalamine itself, this medication is not appropriate for you. Symptoms of a salicylate allergy can include rash, hives, breathing difficulty, or severe stomach pain. If you’ve ever had a reaction to aspirin or similar compounds, make sure your prescriber knows before starting Lialda.
What to Expect on Treatment
During the induction phase, most people take Lialda for about eight weeks to get an active flare under control. Improvement in symptoms like bloody stools, diarrhea, and urgency typically happens gradually over that window rather than overnight. If the medication works well for you, the transition to maintenance dosing is seamless since it’s the same pill, just fewer tablets per day.
Maintenance therapy with Lialda is often long term. Ulcerative colitis is a chronic condition, and stopping medication once you feel better frequently leads to relapse. Many people stay on maintenance mesalamine for years, and the safety profile supports long-term use as long as kidney function is monitored. You may occasionally notice what looks like a tablet in your stool. This is the empty shell of the delivery system after the medication has been released, and it’s normal.